Establishment Labs (NASDAQ:ESTA – Get Free Report) and NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Insider and Institutional Ownership
72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Establishment Labs and NeuroOne Medical Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Establishment Labs | -15.82% | -196.69% | -10.73% |
| NeuroOne Medical Technologies | -71.50% | -128.12% | -86.34% |
Analyst Ratings
This is a summary of current recommendations for Establishment Labs and NeuroOne Medical Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Establishment Labs | 1 | 0 | 9 | 0 | 2.80 |
| NeuroOne Medical Technologies | 1 | 1 | 3 | 0 | 2.40 |
Establishment Labs currently has a consensus target price of $98.56, indicating a potential upside of 54.48%. NeuroOne Medical Technologies has a consensus target price of $7.33, indicating a potential upside of 697.71%. Given NeuroOne Medical Technologies’ higher possible upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Establishment Labs.
Risk and Volatility
Establishment Labs has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.
Valuation & Earnings
This table compares Establishment Labs and NeuroOne Medical Technologies”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Establishment Labs | $211.08 million | 9.01 | -$51.06 million | ($1.31) | -48.70 |
| NeuroOne Medical Technologies | $12.10 million | 0.69 | -$3.61 million | ($0.95) | -0.97 |
NeuroOne Medical Technologies has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
Establishment Labs beats NeuroOne Medical Technologies on 8 of the 14 factors compared between the two stocks.
About Establishment Labs
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
